Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366145 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)
A Phase 3 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT00366145 is a Phase 3 study that has completed, run by Mesoblast. The registered enrollment target is 260 participants.
The verdict
NCT00366145, a Phase 3 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and gather additional safety information for Prochymal® in participants who have failed to respond to steroid treatment of Grades B-D acute GVHD.
Interventions
- DRUG Placebo
- BIOLOGICAL Prochymal®
- DRUG Standard of Care for GVHD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2006-08-17 |
| Est. Completion | 2009-05-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366145
The ClinicalTrials.gov registry entry for NCT00366145 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00366145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366145 about?
NCT00366145 is a clinical study titled "Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)". The purpose of this study is to evaluate the efficacy and gather additional safety information for Prochymal® in participants who have failed to respond to steroid treatment of Grades B-D acute GVHD.
What is the current status of trial NCT00366145?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2006-08-17. Estimated completion is 2009-05-28.
What interventions are being tested in trial NCT00366145?
The interventions under investigation include: Placebo (DRUG), Prochymal® (BIOLOGICAL), Standard of Care for GVHD (DRUG).
Who is sponsoring clinical trial NCT00366145?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.